Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis’s failure in osteoporosis could be bad break for Tarsa

This article was originally published in Scrip

Executive Summary

Novartis’s SMC021 failed to meet main fracture reduction endpoints in osteoporosis Phase III trial. While the result is arguably unsurprising for a calcitonin candidate, it is a setback for other companies such as Tarsa Therapeutics aiming to stimulate growth of the class. Tarsa may now struggle to secure a partner willing to bring its pipeline drug Ostora to the market. Novartis is expected to discontinue development of SMC021 and focus on more attractive targets for osteoporosis treatment.

You may also be interested in...



FDA setback the last straw for Merck's women's health portfolio?

Merck admission that it has received a complete response letter from the FDA for its novel contraceptive Nomac E2 (nomegestrol acetate/17 beta estradiol) may spell the end for more than just this product, analysts at Datamonitor say.

Lilly poised for windfall following FDA approval of Cialis for BPH indications

Eli Lilly is poised to benefit from a windfall after FDA granted marketing authorisation for once daily Cialis (tadalafil) to treat men with BPH symptoms alone or with both BPH and erectile dysfunction. This is the first drug to offer this convenient option to patients. These new indications will provide Eli Lilly with an estimated additional $150m in annual sales for Cialis in the US.

Pfizer’s combo pill could reinvigorate troubled HRT market

New positive Phase III data suggests Pfizer’s new combination pill BZA/CE is safe and effective in treating menopausal symptoms and preventing osteoporosis. While this is promising, approval is not guaranteed as the FDA has had a tough stance on such therapies. Assuming it reaches the US market in 2013, the challenge for Pfizer will be to dispel safety concerns associated with women taking HRT.

Topics

Related Companies

UsernamePublicRestriction

Register

SC015213

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel